LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Medicines for the Treatment Of COVID-19: Awaiting the Evidence.

    Marto, Natalia / Monteiro, Emília C

    Acta medica portuguesa

    2020  Volume 33, Issue 7-8, Page(s) 500–504

    Abstract: ... We review the most promising candidate medicines, including available evidence, clinical recommendations and ... a new illness with no effective treatment or vaccine that has reached pandemic proportions ... the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019 ...

    Abstract The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Chloroquine/therapeutic use ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Drug Combinations ; Drugs, Investigational/therapeutic use ; Global Health ; Humans ; Hydroxychloroquine/therapeutic use ; Lopinavir/therapeutic use ; Off-Label Use ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Ritonavir/therapeutic use ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Drug Combinations ; Drugs, Investigational ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF) ; tocilizumab (I031V2H011) ; Ritonavir (O3J8G9O825) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-05-04
    Publishing country Portugal
    Document type Journal Article ; Review
    ZDB-ID 603078-6
    ISSN 1646-0758 ; 0870-399X
    ISSN (online) 1646-0758
    ISSN 0870-399X
    DOI 10.20344/amp.13908
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2343: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Medicines for the Treatment Of COVID-19: Awaiting the Evidence

    Marto, Natalia / Monteiro, Emília C

    Acta med. port

    Abstract: ... We review the most promising candidate medicines, including available evidence, clinical recommendations and ... a new illness with no effective treatment or vaccine that has reached pandemic proportions ... the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019 ...

    Abstract The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32425152
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Medicines for the Treatment Of COVID-19

    Natalia Marto / Emília C. Monteiro

    Acta Médica Portuguesa, Vol 33, Iss 7-8, Pp 500-

    Awaiting the Evidence

    2020  Volume 504

    Abstract: ... We review the most promising candidate medicines, including available evidence, clinical recommendations and ... a new illness with no effective treatment or vaccine that has reached pandemic proportions ... the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019 ...

    Abstract The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.
    Keywords coronavirus ; coronavirus infections/drug therapy ; covid-19/drug therapy ; Medicine ; R ; Medicine (General) ; R5-920 ; covid19
    Subject code 610
    Language English
    Publishing date 2020-07-01T00:00:00Z
    Publisher Ordem dos Médicos
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Medicinal Plants with Potential Inhibitory Bioactive Compounds against Coronaviruses.

    Adeleye, Olutayo Ademola / Bamiro, Oluyemisi Adebowale / Bakre, Lateef Gbenga / Odeleye, Florence Olubola / Adebowale, Modupe Nofisat / Okunye, Olufemi Lionel / Sodeinde, Mariam Adeola / Adebona, Adannaya Charity / Menaa, Farid

    Advanced pharmaceutical bulletin

    2021  Volume 12, Issue 1, Page(s) 7–16

    Abstract: ... specific treatment for COVID-19 yet, the search for medicinal plants with inhibitory bioactive compounds ... highlighted several evidences to show that medicinal plant used in the treatment of SARSCoV may offer ... some sort of relief from the burden of coronavirus disease 2019 (COVID-19) pandemic. Since there is no ...

    Abstract Medicinal plant is a major source of drug discovery for disease management. Over 85% of the population in Asia and in the Middle East use herbal medicine for disease management such as severe acute respiratory syndrome (SARS) caused by coronavirus. Infection from coronavirus is initiated by entry of the virus into a susceptible host cell. The two human coronaviruses of public health importance two decades ago were SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) and now SARS-CoV-2. These three viruses belong to the same class of beta coronavirus and are somewhat similar in genome sequencing, life cycle, mode of entry into a host, mode of transmission and clinical manifestations. This review identified twenty medicinal plants with potential inhibitory bioactive compounds from natural sources that are active against coronaviruses that could be developed into various drug delivery systems. It also highlighted several evidences to show that medicinal plant used in the treatment of SARSCoV may offer some sort of relief from the burden of coronavirus disease 2019 (COVID-19) pandemic. Since there is no specific treatment for COVID-19 yet, the search for medicinal plants with inhibitory bioactive compounds against coronavirus could be the long awaited breakthrough scientists have been searching to change the narratives of COVID-19 pandemic.
    Language English
    Publishing date 2021-01-30
    Publishing country Iran
    Document type Journal Article ; Review
    ZDB-ID 3018440-X
    ISSN 2251-7308 ; 2228-5881
    ISSN (online) 2251-7308
    ISSN 2228-5881
    DOI 10.34172/apb.2022.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top